HIMS Stock Rises 30% in a Week – The Rally Is Far From Over

Hims & Hers Health (NYSE: HIMS) has been making waves in the stock market, with its stock surging by an impressive 30% over the past week. This recent rally has sparked considerable interest, particularly following significant announcements and strategic moves by the company. Investors are eager to know whether this upward momentum will continue or if it's a temporary spike. Let’s take a closer look at why HIMS stock is gaining so much attention and whether the rally is truly far from over.

The Recent Surge in HIMS Stock

On Tuesday, April 29, HIMS stock rose by 23%, marking a remarkable 30% increase over the past week. The catalyst for this surge came from an exciting partnership between Hims & Hers Health and Novo Nordisk. The global pharmaceutical giant announced it would offer its popular weight loss drug, Wegovy, through select telehealth platforms, including Hims & Hers Health. This move is seen as a significant win for HIMS, especially as it transitions from compounded versions of weight loss drugs to offering branded medications.

This new partnership marks a significant milestone for HIMS, as the company continues to establish itself as a leading provider of telehealth services, particularly in the areas of weight management and health solutions. The ability to offer a high-demand drug like Wegovy through its platform is expected to drive significant growth in the company’s subscriber base and revenue.

HIMS: A Company Positioned for Growth

Hims & Hers Health has been steadily making strides in the telehealth industry. The company has seen impressive growth in its subscriber base, now totaling 2.2 million customers. This expanding base gives HIMS a solid foundation to tap into new revenue streams. The addition of Wegovy to its product offerings is likely to lead to higher average revenue per user (ARPU) and increased average order values (AOV). This, in turn, will contribute to the company's top-line growth.

The move to offer branded medications is particularly significant, as HIMS had previously faced challenges due to drug shortages. With Wegovy now available through its telehealth platform, the company is no longer just selling compounded versions of weight loss drugs. Still, it is instead tapping into a broader market of customers seeking reliable, high-quality medications.

The Strategic Advantage of the Novo Nordisk Partnership

Novo Nordisk’s decision to partner with Hims & Hers Health is a testament to the growing role of telehealth in the healthcare landscape. While Novo Nordisk sells Wegovy through its direct-to-consumer portal, Novocare, for $499 per month (for patients without insurance), telehealth platforms like HIMS are likely to charge a premium. This is due to the added value of bundling Wegovy with other health services that HIMS provides.

For HIMS, this partnership is a strategic opportunity to increase its revenue per subscriber. The weight loss drug Wegovy has become highly sought after, and the addition of such a high-priced medication is likely to lead to a notable increase in both Average Revenue Per User (ARPU) and Average Order Value (AOV). This will also solidify HIMS’s position in the growing market of telehealth and weight management services.

Strong Business Fundamentals Support the Rally

While the partnership with Novo Nordisk is a significant driver of the recent surge in HIMS stock, it is vital to consider the company’s overall business fundamentals. Over the past three years, HIMS has achieved an average annual revenue growth rate of 76%. The company has also maintained a solid adjusted EBITDA margin of 12%, which is a sign of healthy profitability.

Additionally, HIMS has seen its subscriber base quadruple since 2021. This rapid growth in subscribers shows that more people are turning to HIMS for their health and wellness needs. With this solid foundation, the company is well-positioned to continue growing and expanding its offerings, which is why the recent increase in stock price is not surprising.

Valuation and Future Outlook for HIMS Stock

As of now, HIMS stock is trading at $35, which represents a price-to-sales (P/S) ratio of 5.6x. This is higher than its five-year average of 3.3x, but the company’s improved business fundamentals justify the premium valuation. In the past, there was uncertainty surrounding HIMS’s future strategy once drug shortages were resolved. However, with a clear path forward, including offering both branded medications and weight loss treatments, the company’s valuation multiple has increased.

Investors are now more confident in HIMS’s ability to maintain growth, and as a result, the stock is gaining increased attention. The combination of strong subscriber growth, new product offerings, and partnerships with major pharmaceutical companies, such as Novo Nordisk, bodes well for the company’s long-term success.

Is the Rally Over?

Given the strong operational performance and the ongoing improvements in HIMS’s business model, it is highly likely that the stock will continue to rise. The recent surge in stock price reflects investor optimism about the company’s prospects. With the addition of high-demand products like Wegovy to its offerings, HIMS is well-positioned to continue its upward trajectory.

In the coming months, it will be interesting to see how the partnership with Novo Nordisk affects the company's financial performance. If the company can continue to expand its subscriber base and capitalize on its new offerings, the rally may not be far from over.

Conclusion

HIMS stock has experienced a 30% rise in just one week, and the momentum appears likely to continue. With a strong subscriber base, a clear path forward in offering branded medications like Wegovy, and solid financial performance, HIMS is poised for sustained growth. Investors should keep an eye on HIMS stock, as the rally appears to be just the beginning of what could be an exciting journey for the company.

For more news updates, check out this article: ‘I did not fall in love with Dania Shah’; Hakeem Shahzad's statement about his wife.